In Conversation
At Eleusis, we are developing psychedelics for potential therapeutic applications, as well as a care delivery platform that aims to increase the safety, tolerability, and accessibility of any ultimately-approved psychedelic drug therapies. It is a complex path from drug discovery, to preclinical work, to trial design and regulatory submissions, involving selection of potential patient populations, invention of patient monitoring systems, and optimisation of treatment regimes.
